CONNECT WITH US
HealthTech

HealthTech

Sofinnova closes second crossover fund at €725M for late-stage European biotechs

Endpoints News logo

Published on

Add as a preferred source on Google
Sofinnova closes second crossover fund at €725M for late-stage European biotechs

Sofinno­va Part­ners has se­cured €725 mil­lion ($815 mil­lion) for its sec­ond crossover fund, which it said would fill the fi­nanc­ing gap for late-stage Eu­ro­pean bio­phar­ma …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.